There is a real threat of the increasing carbapenemase producing isolates that causes serious hospital-acquired infections and the high mortality rates. The prevalence of carbapenem resistance in
K. pneumoniae isolates was 3.6% to 10.8% in USA according to the center for disease control and prevention (CDC) 2008 report. Meanwhile in Europe, according to European antimicrobial resistance surveillance network (EARS-Net) data, it was reported as 7.3% (
24,
25). In Turkey, the rate of carbepenem resistance was reported in 2.2% of
K. pneumoniae isolates recovered in a university hospital from 2004 to 2007 (
26). Thereafter, the increased resistance rates varying from 3.7% to 16.6% were reported from different hospitals (
27-
29).
In the Hitit-2 surveillance study of 2007 performed on the isolates from 13 hospitals located in different geographic regions of Turkey, the prevalence of carbapenem resistance in
K. pneumoniae was notified as 3.1% ranging from 0 to 16% (
27). Similarly, Kuzucu et al. found 3.6% carbapenem resistance among the
K. pneumoniae isolates from the East part of Turkey in the same time period (
28). Then, the rate of carbapenem resistance slightly increased to 6.8% in 2013 (
29). In agreement with the previous data, the current study showed that 5.8% of
K. pneumoniae isolates recovered from a tertiary hospital in the capital city of Turkey were phenotypically resistant to carbapenems.
Modified Hodge test is a reliable test especially for KPC and
blaOXA-48 producing isolates, but not for MBL producers (
12). Similar to the current study data, the current study found that nearly all ertapenem-resistant
K. pneumoniae isolates with
blaOXA-48 were positive with MHT. Parallel to the current study data, Kuzucu et al., also showed that all of the carbapenem-resistant isolates were MHT positive (
28). In contrast to these results, in another study, MHT positivity was found only in 1 out of 7 isolates with carbapenemase genes (
5), and it was concluded that MHT might be false negative, especially in the presence of ESBL or AmpC with reduced porine activity (
5,
30). In the present study, ECD method was positive in 6.5% of the tested ertapenem-resistant isolates and all of them harbored
blaNDM-1, suggesting high concordance between ECD method and PCR. This result was in agreement with those of the previous reports indicating the reliability of combine disc methods to detect MBL producing isolates (
30,
31).
In the present study, more than 90% of the carbepenem-resistant
K. pneumoniae isolates were
blaOXA-48 positive. This enzyme was firstly reported from a
K. pneumoniae isolate in Turkey in 2001 (
22). Later, it was reported from different hospitals with increased rates (
29,
32). A multi-central surveillance study performed at a Turkish university hospital from 2009 to 2013 showed that more than 96% of
K. pneumoniae isolates harbored
blaOXA-48 carbapenamese (
21). In another multi-central study conducted on the patients from different hospitals of Turkey as part of the European survey of carbapenemase producing
Enterobacteriaceae (EuSCAPE), the high prevalence (83%) of
blaOXA-48 was also confirmed (
33).
In the current study,
blaNDM-1 gene was observed in 6 (6.5%) of the resistant isolates, 4 of them were from clinical samples and 2 from rectal swabs. There were no direct epidemiological link such as common isolation date and/or hospitalized wards between these isolates, except that 2 of them were in the same pulsotype, suggesting that the NDM-1 producer isolates mostly came from different clones. In Turkey, the first NDM-1 positive
K. pneumoniae isolate was reported from the blood culture of a child patient in 2011 (
34). In 2013, the study performed on 94 carbapenem-resistant K. pneumoniae isolates recovered from rectal swab samples of inpatients reported that 4.3% of the isolates produced only NDM-1, and 1% produced both
blaOXA-48 and NDM-1 (
35). Currently, a NDM-1 positive
K. pneumoniae epidemic was described in a tertiary hospital and 2 of the isolates also harbored the
blaOXA-48 (
36). Parallel to the results of Turkey, the emergence of NDM-1 producers among
K. pneumonae and other
Enterobacteriaceae members is reported worldwide, especially from India and Middle East and Far East countries (
37,
38).
Verona integron-encoded MBLs and IMPs are the most common MBLs worldwide especially in Greece, Taiwan, and Japan.
Klebsiella pneumoniae carbapenemase was first reported in 1996, and became more widespread and today is the most common carbapenemase (
3,
7,
39). In the present study, KPC, IMP, and VIM were not determined from any of the isolates. Similar to the current study data, 2 recent studies performed on carbapenem-resistant
K. pneumoniae clinical isolates from different hospitals of Turkey, no positive results for KPC, IMP, and VIM enzymes were reported (
40,
41). In a multicentral surveillance study, the prevalence of VIM, IMP, and KPC among 136 carbapenem-resistant
E. coli and
K. pneumoniae isolates was reported as 2.8%, 1.4%, and 0%, respectively (
33). Based on the results of the current and those of previous studies, it can be speculated that these enzymes are not a major problem in Turkey yet; however, it is worth to follow their incidence.
Pulse-field gel electrophoresis provides very useful data to understand the epidemiology of carbapenem-resistant
K. pneumoniae isolates and to revise and enhance infection control programs to prevent bacterial transmission (
17). In the current study, the results of PFGE showed that more than half of the carbapenem-resistant
K. pneumoniae isolates were identified in clusters and according to the similarity coefficient higher than 85%, clonally relatedness among the tested isolates increased to 80.6%. This result indicated the emergence and spread of these resistant isolates across the hospital. The current study also indicated that cross-transmission was not restricted in a specific clinic or time period. For instance, although the 9
K. pneumoniae isolates clustered in the largest PFGE type, 4 were mainly isolated from the reanimation unit, this clone was also found in 2 other services and it stayed in the studies hospital in a 20-month period. The second largest PFGE type 2 comprised of 7 isolates collected from 4 different samples of the patients in 5 different services during the 6-month period.
The PFGE type 1 included 6 species isolated from the patients hospitalized in 4 different services during a period of 12 months. Similar to the current study, PFGE of multidrug-resistant
K. pneumoniae isolates in Egypt revealed that clonally related strains were isolated from various sources such as different patients in the same hospital and environmental samples (
17). A recent study performed on carbepenem-resistant
K. pneumoniae clinical isolates in Shandog, China, showed that the strains in the same PFGE type were isolated in the same clinic for more than 2 years (
6). As already indicated (
18,
42), the high rate of clonally relatedness among the isolates from different services in a wide time period was an important evidence for ongoing cross-transmission of these resistant isolates in the current study setting. Infected or colonized patients, hospital staff, and/or contaminated equipment might affect this cross-transmission.
5.1. Conclusion
High rate (80.6%) of clonal relationship between the carbapenem-resistant isolates collected in a 3-year period indicates a longtime cross-contamination in study population. Therefore, strict infection control and surveillance measures combined with careful and reasonable use of antibiotics are very important to minimize the spread of carbapenem resistance.